Stimulation of anti-tumor immune response through release of tumor antigens

Stimulation of anti-tumor immune response through release of tumor antigens" describes the process by which dying tumor cells, due to natural cell turnover, cancer therapies, or direct immune attack, release intracellular antigens that are subsequently taken up and presented by antigen-presenting cells such as dendritic cells. This antigen presentation can trigger both the innate and adaptive arms of the immune system, leading to the activation of cytotoxic T lymphocytes and other effector cells capable of recognizing and destroying cancer cells. This process underpins the rationale for numerous cancer immunotherapies, including cancer vaccines, checkpoint inhibitors, and some types of cell therapy, but is not a druggable molecular entity itself[2][3][4][5][6]. Summary: This entry should not be treated as a canonical molecular target. It is instead a mechanistic pathway or immunotherapeutic concept. For formal target annotation, focus should be shifted toward specific molecules involved—such as tumor-associated antigens (TAAs), neoantigens, the cGAS-STING pathway, or immune checkpoint receptors (PD-1, CTLA-4)[2][4][6].

Enhancement of immunogenicity of tumor cells by exposure of tumor-associated antigens; Activation of adaptive immune response targeting neoantigens or tumor-associated antigens